FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:328-330 January 25, 2007 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Audio Interview Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Under ideal conditions, large clinical trials would be designed so that they satisfied the marketing needs of the pharmaceutical manufacturers that generally sponsor them and, at the same time, answered important clinical questions that may have a major influence on public health. In practice, however, alternative choices in trial design often favor one of these two goals. The choice of the reference treatment in active-comparator studies is an excellent example.

For nonsteroidal antiinflammatory drugs (NSAIDs), which all relieve arthritis pain, the question of greatest interest in randomized trials involves the incidence of adverse events. The more selective cyclooxygenase-2 (COX-2) inhibitors . . . [Full Text of this Article]

Source Information

Dr. Psaty is a professor and codirector of the Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, and the Center for Health Studies, Group Health, Seattle; and Dr. Weiss is a professor in the Department of Epidemiology, University of Washington, Seattle.

An interview with Robert Califf, vice chancellor for clinical research at Duke University, can be heard at www.nejm.org.

This article has been cited by other articles:

• Panoulas, V. F., Metsios, G. S., Pace, A. V., John, H., Treharne, G. J., Banks, M. J., Kitas, G. D. (2008). Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 47: 1286-1298 [Abstract] [Full Text]  
• Schwartz, J. I., Dallob, A. L., Larson, P. J., Laterza, O. F., Miller, J., Royalty, J., Snyder, K. M., Chappell, D. L., Hilliard, D. A., Flynn, M. E., Cavanaugh, P. F. Jr, Wagner, J. A. (2008). Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX-2 Versus COX-1 in Healthy Subjects. J Clin Pharmacol 48: 745-754 [Abstract] [Full Text]  
• Frolov, R. V., Berim, I. G., Singh, S. (2008). Inhibition of Delayed Rectifier Potassium Channels and Induction of Arrhythmia: A NOVEL EFFECT OF CELECOXIB AND THE MECHANISM UNDERLYING IT. J. Biol. Chem. 283: 1518-1524 [Abstract] [Full Text]  
• Psaty, B. M., Charo, R. A. (2007). FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part. JAMA 297: 1917-1920 [Full Text]  
• Antman, E. M., Bennett, J. S., Daugherty, A., Furberg, C., Roberts, H., Taubert, K. A. (2007). Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation 115: 1634-1642 [Full Text]  
• (2007). Drug safety is too important to leave to industry. BMJ 334: 230-230 [Full Text]